In 2015, Le et al. first evaluated the clinical activity of pembrolizumab, an anti-PD-1 immune checkpoint inhibitor, in 41 patients presenting with progressive metastatic colorectal cancer (CRC) with or without MMR deficiency or other MMRd cancers. This evidence concerns the gene PDCD1 and cancer.